Which Vaccines and Why: The Evidence and the Deals
Feb 5, 2021
In December 2019, SARS-CoV2 announced itself to the world as an entirely brand-new pathogen. We had no data to work with (except experience with other coronaviruses), no immunity in any human population, no therapeutics and of course no vaccines. The global scientific community has made extraordinary progress in learning about this deadly virus and creating tools to combat it. As of 4th February 2021, there are 208 vaccine trials, 79 candidates and 11 vaccines that have been approved by at least one country.1
Operation Vaccination: An Analysis of Global COVID-19 Vaccine Rollout Strategies is a weekly post which will explore the policy, logistics, obstacles and controversies involved in procuring and distributing vaccines against COVID-19.
These articles are a means for the WFPHA to keep readers up to date with how the vaccine race is developing across the world.
The theme of this week is “Which Vaccines and Why: The Evidence and the Deals”.
The table in the link below outlines which vaccines have been approved and/or how many doses have been secured by 9 countries (Brazil, India, Indonesia, Ireland, Israel, Nigeria, Taiwan, U.K. and U.S.) and COVAX. Every effort has been made to ensure this information is as accurate as possible at the time of writing.
There is also an article about each of the vaccines being rolled out by these nations (Pfizer/BioNTech, Moderna, Oxford/AstraZeneca, Sinovac, Covishield & Covaxin). The posts discuss their origins, evidence supporting safety and efficacy, and other key points relating to their potential use as a weapon in the fight against COVID-19.
If you have any feedback or specific questions you would like answered, please feel free to contact us.